Tuesday, July 23, 2024

AI Medical Stock Landing Massive Contracts

AN OXFORD CLUB PUBLICATION

AI Medical Stock Landing Massive Contracts

James Ogletree, Managing Editor, The Oxford Club

Dear Wealthy Retirement Reader,

Few people know its name, but Intuitive Surgical was one of the five best stocks of the last 20 years.

It went up as much as 18,000% in two decades.

Why?

Because it used new technology - surgical robotics - to drive sales sky high.

Now... another company is following its path.

The company is tiny today - just $500 million - but it is in position to grow dramatically.

In short, it is the inventor of the world's first AI-designed drug to enter clinical trials.

And Big Pharma is lining up to use its patent-protected technology.

Merck is collaborating with them on three projects that could generate up to $674 million in revenue.
French pharma giant Sanofi agreed to pay the company up to $5.2 billion to develop 15 new drugs.
Bristol Meyers Squibb signed a $1.2 billion partnership with the company.

You can see... each one of these projects is worth more than the entire market cap of this new AI stock!

In short, the upside is MASSIVE.

Which is why I wanted to send you this video.

It comes from one of the great stock pickers of all time - a man who actually recommended Intuitive Surgical in real time back in 2004.

In fact, he called 4 of the 6 top-performing stocks from 2000 to 2020.

And he says this new company is the #1 AI Stock Under $10.

Watch his free video breaking down the situation here.

Sincerely,

James

P.S. He's recommending a specific financial move to profit on this stock... one that a Kansas welder used to get on the Forbes richest list.

See what he's recommending right here.

You are receiving this email because you subscribed to Wealthy Retirement.
Wealthy Retirement is published by The Oxford Club.

To stop receiving special invitations and offers from Wealthy Retirement, please click here.
Please note: This will not impact the fulfillment of your subscription in any way.

Questions? Check out our FAQs. Trying to reach us? Contact us here.
Please do not reply to this email as it goes to an unmonitored inbox.

Nothing published by The Oxford Club should be considered personalized investment advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed personalized investment advice. We allow the editors of our publications to recommend securities that they own themselves. However, our policy prohibits editors from exiting a personal trade while the recommendation to subscribers is open. In no circumstance may an editor sell a security before subscribers have a fair opportunity to exit. The length of time an editor must wait after subscribers have been advised to exit a play depends on the type of publication. All other employees and agents must wait 24 hours after publication before trading on a recommendation.

Any investments recommended by The Oxford Club should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company.

Protected by copyright laws of the United States and international treaties. The information found on this website may only be used pursuant to the membership or subscription agreement and any reproduction, copying or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of The Oxford Club, LLC, 105 West Monument Street, Baltimore, MD 21201.

Tuesday, July 23, 2024